Day One Biopharmaceuticals, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Day One Biopharmaceuticals reports significant product revenue growth for OJEMDA in Q3 2025, alongside increased net losses and strategic program adjustments.
NASDAQ
Day One Biopharmaceuticals reports significant revenue growth driven by OJEMDA sales, alongside strategic pipeline adjustments and a strong cash position.
NASDAQ
10-Q: Day One Biopharmaceuticals Reports First Quarter 2025 Financial Results, Driven by OJEMDA Sales
Day One Biopharmaceuticals reports a net product revenue of $30.5 million from OJEMDA sales in the first quarter of 2025, alongside a net loss of $36.0 million.
NASDAQ
Day One Biopharmaceuticals reports a strong third quarter, marked by the commercial launch of OJEMDA and a significant licensing agreement with Ipsen, resulting in substantial revenue growth.
NASDAQ
Day One Biopharmaceuticals reports second quarter 2024 results, including initial OJEMDA sales and a significant licensing agreement with Ipsen for ex-US commercialization.
NASDAQ
Day One Biopharmaceuticals announced its first quarter 2024 results, including a net loss of $62.4 million, and highlighted the FDA approval of OJEMDA for pediatric low-grade glioma.